Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance [0.03%]
集成的多组学谱分析揭示了两种具有预后意义的脾边缘区淋巴瘤亚型
Helen Parker,Amatta Mirandari,Ben Stevens et al.
Helen Parker et al.
Splenic marginal zone lymphoma (SMZL) is a rare B-cell malignancy with notable genetic, epigenetic, and clinical heterogeneity. This study utilized coding and non-coding sequencing (n=74), including whole-genome sequencing (WGS) on 24 paire...
A comprehensive multicenter study assessing the impact of abelacimab, asundexian and milvexian on coagulation assays [0.03%]
一项关于艾伯来昔单抗、阿孙迪沙然和密尔维沙然对凝血检测影响的全面多中心研究
Laurie Goubeau,Emmanuel Curis,Xavier Delavenne et al.
Laurie Goubeau et al.
Phase 3 trials evaluating inhibitors of coagulation factor (F) XI and/or its activated form (FXIa) as novel anticoagulant drugs are ongoing. These agents include parenteral monoclonal antibody (abelacimab) and oral small molecules (milvexia...
DUSP1 is a Key Driver of Disease Persistence and Potential Therapeutic Target in Hairy Cell Leukemia [0.03%]
DUSP1是毛细胞白血病疾病持续存在的重要驱动因素及潜在治疗靶点
Jan-Paul Bohn,Alexandra Scheiber,Gregor Sturm et al.
Jan-Paul Bohn et al.
Classic hairy cell leukemia (HCL) is a rare indolent B cell lymphoproliferative disorder characterized by the driver mutation BRAF V600E. Standard treatment with purine analogs (i.e. cladribine) induces long-term remissions, but up to 25% o...
Successful gene therapy for transfusion-dependent α-thalassemia: a case report [0.03%]
α-地中海贫血输血依赖型基因治疗1例报告
Xiaolin Yin,Linxia Qian,Guoyi Dong et al.
Xiaolin Yin et al.
Alpha-thalassemia is a severe inherited hemoglobin disorder with limited curative options for transfusion-dependent patients lacking suitable donors. We report the first-in-human application of lentiviral vector-mediated α-globin gene ther...
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML [0.03%]
阿扎胞苷、维奈克拉和吉列替尼治疗新诊断的FLT3突变型AML的长期结局
Nicholas J Short,Hagop M Kantarjian,Naval G Daver et al.
Nicholas J Short et al.
In patients with FLT3-mutated AML who receive frontline azacitidine plus venetoclax, relapses are commonly driven by expansion of the FLT3-mutated clone, providing rationale for "triplet" FLT3 inhibitor-based lower-intensity regimens. Here ...
Nascent Pre-Platelets and B4GALT1 Glycosylation Contribute to 5-FU-induced Bone Marrow Recovery [0.03%]
新生的预血小板和B4GALT1糖基化有助于5-FU引起的骨髓恢复
Natalia Weich,Leonardo Rivadeneyra,Alejandro Roisman et al.
Natalia Weich et al.
While megakaryocytes (MKs) are essential for hemostasis, vascular integrity, and hematopoietic stem and progenitor cells (HSPCs) support, their role in bone marrow (BM) recovery has remained underexplored. Here, using a 5-fluorouracil (5-FU...
Baricitinib for refractory chronic graft-versus-host-disease: Results of a phase 1/2 study [0.03%]
巴利昔单抗治疗难治性慢性移植物抗宿主病Ⅰ/Ⅱ期临床研究结果
Noa G Holtzman,Annie Im,Lauren M Curtis et al.
Noa G Holtzman et al.
Refractory chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation remains a leading cause of late morbidity and mortality for transplant survivors. Therapeutic targeting of the JAK-STAT pathway has pro...
Andrew M Brunner
Andrew M Brunner
Allison L Bartlett,Ashish Kumar
Allison L Bartlett
Jaap Jan Boelens,Christopher C Dvorak
Jaap Jan Boelens